BNP Paribas Has $6.58 Million Stake in Boston Scientific Corporation $BSX

BNP Paribas trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 26.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,752 shares of the medical equipment provider’s stock after selling 25,362 shares during the period. BNP Paribas’ holdings in Boston Scientific were worth $6,576,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the last quarter. Rathbones Group PLC boosted its position in Boston Scientific by 20.9% during the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after acquiring an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC bought a new stake in Boston Scientific during the fourth quarter valued at $1,477,000. Kepler Cheuvreux Suisse SA bought a new stake in Boston Scientific during the third quarter valued at $26,955,000. Finally, Waycross Partners LLC bought a new stake in Boston Scientific during the fourth quarter valued at $2,384,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the transaction, the director owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $47.95 on Tuesday. Boston Scientific Corporation has a fifty-two week low of $47.35 and a fifty-two week high of $109.50. The stock has a market cap of $71.28 billion, a price-to-earnings ratio of 20.06, a PEG ratio of 0.89 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm’s 50-day simple moving average is $59.79 and its 200 day simple moving average is $78.08.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter last year, the firm earned $0.75 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of research analyst reports. Evercore cut their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, February 6th. Truist Financial cut their price objective on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, April 23rd. Finally, Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $87.42.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.